Characterization of 298 patients with lung cancer harboring MET Exon 14 skipping alterations

Journal of Thoracic Oncology

Volumn 11, Issue 9, 2016, Pages 1493-1502

  Schrock, Alexa B ^a   Frampton, Garrett M ^a   Suh, James ^a   Chalmers, Zachary R ^a   Rosenzweig, Mark ^a   Erlich, Rachel L ^a   Halmos, Balazs ^b   Goldman, Jonathan ^c   Forde, Patrick ^d   Leuenberger, Kurt ^e   Peled, Nir ^f   Kalemkerian, Gregory P ^g   Ross, Jeffrey S ^a,h   Stephens, Philip J ^a   Miller, Vincent A ^a   Ali, Siraj M ^a   Ou, Sai Hong Ignatius ⁱ  

^a FOUNDATION MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c UCLA MEDICAL CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e Oncology Hematology Care Inc   (United States)

^f Davidoff Cancer Center   (Israel)

^g UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^h ALBANY MEDICAL COLLEGE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Genomic profiling; Lung cancer; Met exon 14 alterations; Met exon 14 skipping; Met y1003 mutation; Splice site mutations

Indexed keywords

CRIZOTINIB; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MICROTUBULE ASSOCIATED PROTEIN 4; PROTEIN MDM2; SCATTER FACTOR RECEPTOR; UBIQUITIN PROTEIN LIGASE E3; MET PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER THERAPY; EPITHELIAL MESENCHYMAL TRANSITION; EXON SKIPPING; FEMALE; GENE DOSAGE; HUMAN; INDEL MUTATION; LARGE CELL CARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SARCOMATOID CARCINOMA; SMOKING; SQUAMOUS CELL CARCINOMA; ANTAGONISTS AND INHIBITORS; EXON; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS C-MET; SMOKING;

EID: 84987809947     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.06.004     Document Type: Article

References (29)

1. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311:1998-2006.
2. Farago AF, Le LP, Zheng Z, et al. Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer. J Thorac Oncol. 2015;10:1670-1674.
3. Cui JJ. Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress. J Med Chem. 2014;57:4427-4453.
4. Okuda K, Sasaki H, Yukiue H, Yano M, Fujii Y. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci. 2008;99:2280-2285.
5. Kazandjian D, Blumenthal GM, Chen H-Y, et al. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancerwith anaplastic lymphoma kinase rearrangements. Oncologist. 2014;19:e5-e11.
6. Weitzman SP, Cabanillas ME. The treatment landscape in thyroid cancer: A focus on cabozantinib. Cancer Manag Res. 2015;7:265-278.
7. Yoshioka H, Azuma K, Yamamoto N, et al. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-Type epidermal growth factor receptor (ATTENTION study). Ann Oncol. 2015;26:2066-2072.
8. Scagliotti G, Pawel J von, Novello S, et al. Phase III multinational, randomized, double-blind, placebocontrolled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-smallcell lung cancer. J Clin Oncol. 2015;33:2667-2674.
9. Ma PC, Kijima T, Maulik G, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 2003;63:6272-6281.
10. Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in nonsmall cell lung cancer. Cancer Res. 2005;65:1479-1488.
11. Kong-Beltran M, Seshagiri S, Zha J, et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res. 2006;66:283-289.
12. Abella JV, Peschard P, Naujokas MA, et al. Met/hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Mol Cell Biol. 2005;25:9632-9645.
13. Togashi Y, Mizuuchi H, Tomida S, et al. MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor. Lung Cancer. 2015;90:590-597.
14. Onozato R, Kosaka T, Kuwano H, Sekido Y, Yatabe Y, Mitsudomi T. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.J Thorac Oncol. 2009;4:5-11.
15. Reungwetwattana T, Ou SH. MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approval. Transl Lung Cancer Res. 2015;4:820-824.
16. Heist RS, Shim HS, Gingipally S, et al. METexon 14 skipping in non-small cell lung cancer. Oncologist. 2016;21:481-486.
17. Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015;5:850-859.
18. Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31:1023-1031.
19. Peschard P, Ishiyama N, Lin T, Lipkowitz S, Park M. A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation. J Biol Chem. 2004;279:29565-29571.
20. Lee J-H, Gao CF, Lee CC, Kim MD, Vande Woude GF. An alternatively spliced form of Met receptor is tumorigenic. Exp Mol Med. 2006;38:565-573.
21. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543-550.
22. Liu X, Jia Y, Stoopler MB, Shen Y, Cheng H, Chen J, et al. Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations. J Clin Oncol. 2015;34:794-802.
23. Tong JH, Yeung SF, Chan AW, et al. MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis. Clin Cancer Res. 2016;22:3048-3056.
24. Awad MM, Oxnard GR, Jackman DM, et al. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression. J Clin Oncol. 2016;34:721-730.
25. Peschard P, Fournier TM, Lamorte L, et al. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell. 2001;8:995-1004.
26. Ou S-HI. Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy? J Clin Pathol. 2013 Oct;66:839-846.
27. Mendoza M, Mandani G, Momand J. The MDM2 gene family. Biomol Concepts. 2014;5:9-19.
28. Zhao Y, Yu H, Hu W. The regulation of MDM2 oncogene and its impact on human cancers. Acta Biochim Biophys Sin. 2014;46:180-189.
29. Mohapatra B, Ahmad G, Nadeau S, et al. Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases. Biochim Biophys Acta. 2013;1833:122-139.